Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

(2019) D.S. Bakker et al.   BRITISH JOURNAL OF DERMATOLOGY

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

(2019) Sarah Faiz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

(2018) William W. Busse et al.   ADVANCES IN THERAPY

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

(2018) J.R. Chalmers et al.   BRITISH JOURNAL OF DERMATOLOGY

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

(2018) M. de Bruin-Weller et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment

(2018) Andreas Wollenberg et al.   Journal of Allergy and Clinical Immunology-In Practice

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

(2018) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

(2018) Karin Jonstam et al.   ALLERGY

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

(2017) Judith L. Thijs et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

(2016) Claus Bachert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

(2014) Jennifer D. Hamilton et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

(2012) Julia K. Gittler et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment

(2011) Hein A.W. van Onzenoort et al.   HYPERTENSION